CN109568420A - The purposes of Chinese wampee seed and its extract in the food, health care product or drug of preparation treatment diabetes, obesity and hyperlipidemia - Google Patents
The purposes of Chinese wampee seed and its extract in the food, health care product or drug of preparation treatment diabetes, obesity and hyperlipidemia Download PDFInfo
- Publication number
- CN109568420A CN109568420A CN201710909565.5A CN201710909565A CN109568420A CN 109568420 A CN109568420 A CN 109568420A CN 201710909565 A CN201710909565 A CN 201710909565A CN 109568420 A CN109568420 A CN 109568420A
- Authority
- CN
- China
- Prior art keywords
- extract
- chinese wampee
- water
- wampee seed
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 79
- 235000008738 Clausena lansium Nutrition 0.000 title claims abstract description 53
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 235000013305 food Nutrition 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title claims abstract description 16
- 230000036541 health Effects 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 10
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 9
- 208000008589 Obesity Diseases 0.000 title claims abstract description 7
- 235000020824 obesity Nutrition 0.000 title claims abstract description 7
- 241000757020 Pontederia Species 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 claims abstract 2
- 244000089795 Clausena lansium Species 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 34
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- 235000019441 ethanol Nutrition 0.000 claims description 17
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical group CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 239000003960 organic solvent Substances 0.000 claims description 10
- 206010022489 Insulin Resistance Diseases 0.000 claims description 9
- 235000006662 Lansium Nutrition 0.000 claims description 9
- 241001156382 Lansium Species 0.000 claims description 9
- 239000003208 petroleum Substances 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 230000000968 intestinal effect Effects 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 5
- 241001093501 Rutaceae Species 0.000 claims description 4
- 238000005238 degreasing Methods 0.000 claims description 4
- 239000004575 stone Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 241001292317 Clausena Species 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000000638 solvent extraction Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 239000008103 glucose Substances 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 150000002632 lipids Chemical class 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 230000002218 hypoglycaemic effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000010241 blood sampling Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000021590 normal diet Nutrition 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 4
- 102000007330 LDL Lipoproteins Human genes 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 238000007446 glucose tolerance test Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 229940122355 Insulin sensitizer Drugs 0.000 description 2
- 150000007945 N-acyl ureas Chemical class 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 210000004013 groin Anatomy 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 239000000837 restrainer Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 241000905661 Bacteroidetes bacterium Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000164875 Firmicutes bacterium Species 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010049077 Hernia pain Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- YAJCHEVQCOHZDC-QMMNLEPNSA-N actrapid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3N=CNC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@H](C)CC)[C@H](C)CC)[C@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C(N)=O)C1=CNC=N1 YAJCHEVQCOHZDC-QMMNLEPNSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 1
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides the purposes of Chinese wampee seed and its extract in preparation prevention and/or treatment diabetes, obesity, the food of hyperlipidemia, health care product or drug.The present invention also provides new Chinese wampee seed extracts.Chinese wampee seed and extract of the present invention can effectively prevent and/or treat diabetes, obesity, hyperlipidemia, have a vast market application prospect.
Description
Technical field
The present invention relates to Chinese wampee seeds and its extract to prepare the food for the treatment of diabetes, obesity and hyperlipidemia, protect
Purposes in strong product or drug.
Background technique
Diabetes are a kind of metabolic diseases characterized by hyperglycemia.According to World Health Organization 2016, China
There are about 1.1 hundred million diabetics to bring to human health and social economy and seriously affect wherein 90% is diabetes B.
Currently, the therapeutic agent of diabetes B clinically is more, mainly there is insulin secretion stimulators (yellow ureide derivative
With non-yellow ureide derivative), biguanides, alpha-glucosidase restrainer, insulin sensitizer (thiazolidinediones) and crude drug
Object and Chinese patent drug class etc..But yellow sulfonylurea easily causes hypoglycemia, alpha-glucosidase restrainer can cause enteron aisle not
Suitable, insulin sensitizer increases lipocyte proliferation, leads to weight gain, or even fat.These all limit existing anti-glycosuria
Medicine is widely used.Therefore, there is an urgent need to the stronger while safer antidiabetic medicine of activity or health care foods now
Product.
Calusena lansium is a kind of tropical fruit (tree), is Rutaceae (Rutaceae) plant in the civil good reputation for being known as " treasured in fruit "
The fruit of Calusena lansium (Clausena lansium (Lour.) Skeels) is mainly distributed on southwest and Guangdong, Guangxi, Hainan, good fortune
It builds, the ground such as Taiwan.Chinese wampee seed is the seed of Calusena lansium, is in flat oval type, shows more smooth, plants skin book and crisp, more broken to fall off.
Calusena lansium core bitter, warm-natured, distributed in lung channel, stomach meridian are south of the Five Ridges traditional herbal medicine, have detoxicating and resolving a mass, promoting the circulation of qi first recorded in " south of the Five Ridges gather medicinal herbs record "
Analgesic, stomach invigorating detumescence and other effects cure mainly stagnation of the circulation of vital energy epigastric pain, hernia pain, dysmenorrhoea, treating rheumatic ostealgia, children head sore, centipde-bite
Deng.
Currently, having the extract of document report Chinese wampee leaf and Chinese wampee bark has intelligence development, liver protection, hypoglycemic, drop blood
Rouge, oxidation resistant effect.Wherein, the methanolic extract of Chinese wampee bark can effectively reduce the blood glucose level of rat, promote pancreas
The secretion of island element；A series of carbazole alkaloids found in Calusena lansium pericarp are able to suppress alpha-glucosidase, to play hypoglycemic
Effect.
But have no Chinese wampee seed in the report of hypoglycemic reducing blood lipid related fields both at home and abroad at present.
Summary of the invention
To solve the above-mentioned problems, technical solution of the present invention provides Chinese wampee seed and its extract and prevents in preparation
And/or the purposes in treatment diabetes, obesity, the food of hyperlipidemia, health care product or drug.
Further, the Chinese wampee seed is rutaceae Calusena lansium Clausena lansium (Lour.) Skeels
Fruit stone.
Further, the extract of the Chinese wampee seed is water extract or extractive with organic solvent.
Further, the water extract of the Chinese wampee seed is prepared as follows: being taken Chinese wampee seed, is crushed, add water
It extracts at 25 ± 5 DEG C 3 times, extracts 24~72 hours every time, filtering, merging filtrate is concentrated to get water extract.
Further, the w/v of the Chinese wampee seed and water is 1g:(3~5) ml.
Further, the extractive with organic solvent of the Chinese wampee seed is prepared as follows:
1) Chinese wampee seed is taken, is crushed, with petroleum ether degreasing, filtering；
2) filter residue obtained by step 1) is taken, ethyl alcohol is added and extracts, is concentrated to get medicinal extract；
3) medicinal extract obtained by step 2) is taken, it is soluble in water, with extracting n-butyl alcohol, water position is collected, is concentrated to get organic solvent
Extract.
Further, in step 1), the w/v of Chinese wampee seed and petroleum ether is 1g:(3~5) ml.
Further, in step 2), the w/v of filter residue and ethyl alcohol is 1g:(3~5) ml.
Further, in step 2), the volumetric concentration of ethyl alcohol is 65~95%；Preferably, the volumetric concentration of ethyl alcohol is
95%.
Further, in step 3), the w/v of medicinal extract and water is 1g:(5~8) ml.
The present invention provides a kind of Chinese wampee seed water extracts, it is characterised in that: takes Chinese wampee seed, crushes, add water 25
It extracts at ± 5 DEG C 3 times, extracts 24~72 hours every time, filtering, merging filtrate is concentrated to get water extract.
Further, the w/v of the Chinese wampee seed and water is 1g:(3~5) ml.
The present invention also provides a kind of Chinese wampee seed extractive with organic solvent, it is characterised in that: it is as follows
Preparation:
1) Chinese wampee seed is taken, is crushed, with petroleum ether degreasing, filtering；
2) filter residue obtained by step 1) is taken, ethyl alcohol is added and extracts, is concentrated to get medicinal extract；
3) medicinal extract obtained by step 2) is taken, is dissolved in distilled water, with extracting n-butyl alcohol, water position is collected, is concentrated to get organic
Solvent extractable matter.
Further, in step 1), the w/v of Chinese wampee seed and petroleum ether is 1g:(3~5) ml.
Further, in step 2), the w/v of filter residue and ethyl alcohol is 1g:(3~5) ml.
Further, in step 2), the volumetric concentration of ethyl alcohol is 65-95%；Preferably, the volumetric concentration of ethyl alcohol is
95%.
Further, in step 3), the w/v of medicinal extract and water is 1g:(5~8) ml.
The present invention provides use of the said extracted object in the food, health care product or drug of preparation enhancing insulin sensitivity
On the way.
The present invention provides purposes of the said extracted object in the food, health care product or drug for preparing balance intestinal flora.
Test result shows: Chinese wampee seed and extract of the present invention have fabulous hypoglycemic, weight-reducing, lipid-loweringing and balance
The effect of intestinal flora, has a vast market application prospect.
Obviously, above content according to the present invention is not being departed from according to the ordinary technical knowledge and customary means of this field
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification, replacement or change of other diversified forms can also be made.
The specific embodiment of form by the following examples remakes further specifically above content of the invention
It is bright.But the range that this should not be interpreted as to the above-mentioned theme of the present invention is only limitted to example below.It is all to be based on above content of the present invention
The technology realized all belongs to the scope of the present invention.
Detailed description of the invention
Fig. 1 is the glucose tolerance test of mouse after administration, and wherein * indicates that low dose group and model group difference are aobvious
It writes, * * indicates low dose group and model group difference highly significant.# indicates that high dose group and model group significant difference, ## indicate high
Dosage group and model group difference highly significant.
Fig. 2 is after being administered, and the insulin resistance of mouse is tested, and wherein * indicates that low dose group and model group difference are aobvious
It writes, * * indicates low dose group and model group difference highly significant.# indicates that high dose group and model group significant difference, ## indicate high
Dosage group and model group difference highly significant.
Fig. 3 is influence of the extract of the present invention to mouse intestinal flora.
Specific embodiment
The preparation of embodiment 1, extract of the present invention
(1) Chinese wampee seed of acquisition is selected, it dries in the shade naturally, takes 2.5kg fruit stone, smash it through 40 meshes, with 3~5 times
The petroleum ether of amount (ml/g) is stored at room temperature extraction 3 times, and one to three days every time, filter residue was stayed in filtering.
(2) filter residue in step (1) is taken, the 95%V/V ethyl alcohol of 3~5 times of amounts (ml/g) is added, is stored at room temperature extraction 3 times, often
Secondary one to three days, filtering, merging filtrate was concentrated to give Chinese wampee seed ethanol extract medicinal extract 120g.
(3) take medicinal extract obtained by step (2), the distilled water of 5-8 times of amount (ml/g) added to dissolve, then plus with distilled water in equal volume
Extracting n-butyl alcohol 3 times, water position is retained after extraction.
(4) water position obtained by step (3) is filtered to remove insoluble impurities, yellow, viscous solid is concentrated under reduced pressure to obtain
71.5g, as required extract.
The preparation of embodiment 2, extract of the present invention
The Chinese wampee seed of acquisition is selected, it dries in the shade naturally, takes 1.2kg fruit stone, smash it through 40 meshes, measured with 3~5 times
(ml/g) distilled water is stored at room temperature extraction 3 times, and one to three days every time, yellowish-brown was concentrated under reduced pressure to obtain in filtering, combined extract
Thick solid 43.2g, as required extract.
The beneficial effect of extract of the present invention is illustrated below by way of the mode of test example
Test example 1
1, material
1.1, test medicine: the Chinese wampee seed extract for taking above-described embodiment 1 or 2 to prepare is configured to concentration with water respectively
For the solution of 400mg/l and 800mg/l.
1.2, experimental animal: C57BL/6 mouse, SPF grades, male, health science institute, University of Macao Experimental Animal Center
It provides.Animal house temperature is 22 ± 1 DEG C, 40~70%, 12 hour daily cycle of humidity, ad lib drinking-water.
2, mouse model
It gives 26 mouse to normal diet under experimental situation to raise one week, is randomly divided into two groups after adaptation environment, one
Group is given normal diet (normal diet control group, RD, 6), and another group is given high lipid food (TP23000, Nantong spy's network phenanthrene are dynamic
Object feed technology Co., Ltd, it is fatty containing 45%, 20).After eight weeks, mouse weight, the blood after measuring fasting in 16 hours are weighed
Sugar level, when high lipid food mouse fasting blood-glucose than normal diet control group significant raising, it is believed that modeling success.
3, experimental method
Administration route: oral administration gavage administration.
Dosage: the mouse of the successful feeding high lipid food of modeling is randomly divided into 3 groups, hyperlipidemia model group (HFD) 6
Only, low dosage administration group (HP.L) 7, high dose administration group (HP.H) 7.HP.L group awards the extraction of 400mg/kg weight
Object, HP.H group award the extract of 800mg/kg weight, and normal diet control group (RD) and hyperlipidemia model group (HFD) are given identical
The distilled water of volume, is administered once a day, and successive administration eight weeks.
The experiment of 3.1 blood glucose
Fasting blood-glucose test: after mouse fasting 16 hours, tail point blood sampling surveys mouse blood sugar concentration with blood glucose meter, specific to tie
Fruit is shown in Table 1.
Glucose tolerance test: after mouse fasting 16 hours, it is dense to survey mouse basal plasma glucose with blood glucose meter for tail point blood sampling
Then the glucose solution of 2mg/kg weight is injected intraperitoneally in degree, the tail point blood sampling respectively after 15,30,60,90,120 minutes,
Mouse blood sugar concentration is surveyed with blood glucose meter.
Insulin resistance experiment: after mouse fasting 6 hours, tail point blood sampling surveys mouse basal plasma glucose concentration with blood glucose meter,
Then actrapid monotard's solution of 1.0U/kg weight is injected intraperitoneally, the tail point blood sampling respectively after 15,30,60,90,120 minutes,
Mouse blood sugar concentration is surveyed with blood glucose meter.
3.2, fat experiment
Weight and organ coefficient: weighing mouse weight, dissects mouse, takes epididymal adipose, groin adipose tissue, liver
Dirty and kidney, weighs in the balance respectively, and calculates organ coefficient.
3.3, blood lipid is tested
Analysis of blood lipid: after mouse fasting 16 hours, plucking eyeball and take blood, be centrifuged 10 minutes after blood clotting in 3500r/min, will be upper
Layer serum transfers, illustrate to measure serum total cholesterol respectively according to total cholesterol and low-density lipoprotein kit (Nanjing is built up)
With low-density lipoprotein content.
3.4, intestinal flora is tested
Analysis of intestinal microflora: experiment mice is individually placed in metabolism cage tool, 24 hours fecal specimens are collected, in -80 DEG C
Refrigerator freezing saves.DNA sample is extracted using Qiaamp excrement NDA extracts kit, next uses primer 338F (5'-
ACTCCTACGGGAGGCAGCA-3') and 806R (5'-GGACTACCAGGGTATCTAAT-3') expands bacterial 16 S ribosomal
RNA finally utilizes QIIME Platform Analysis flora type (Shanghai Mei Ji Biotechnology Co., Ltd).
4, experimental result
4.1, blood glucose is tested
Fasting blood-glucose test result is shown in Table 1.
The internal hypoglycemic activity of 1 Chinese wampee seed extract of table
Note: * is indicated and model group significant difference.
Glucose tolerance test the result is shown in Figure 1；
Experimental result is shown in Fig. 2 for insulin resistance.
Experimental result explanation: compared with model group, it is small that high lipid food feeding can be reduced after extract drug treatment of the present invention
The fasting blood glucose level of mouse, low dose group and high dose group blood glucose rate of descent are respectively 16.97% and 22.15%, in glucose
In tolerance test, low dose group and high dose group can accelerate the clearance rate of glucose, and in insulin resistance reality
In testing, low dose group and high dose group can enhance insulin sensitivity.Show that extract of the present invention has fabulous drop blood
Sugar, enhances the effect of insulin sensitivity, and shows certain concentration dependent.
4.2, fat experiment
Weight and organ coefficient the results are shown in Table 2 and table 3.
The effect of the obese mouse weight to high lipid food induction of 2 Chinese wampee seed extract of table
Note: * * is indicated and model group difference highly significant.
3 Chinese wampee seed extract of table to the adipose tissues of high lipid food induction, liver and kidney weight
Effect
Note: * * is indicated and model group difference highly significant.
Experimental result explanation: compared with model group, high lipid food feeding can be reduced after extract drug treatment of the present invention and is led
The mouse weight of cause increases, and low dose group and high dose group weight loss rate are respectively 4.04% and 3.81%, in addition epididymis rouge
The weight of fat tissue, groin adipose tissue is remarkably decreased after extract of the present invention administration, and the weight of liver and kidney is not
It influences.Show that extract of the present invention has fabulous antiobesity action, and shows certain concentration dependent.
4.3, blood lipid is tested
Analysis of blood lipid the results are shown in Table 4.
The effect to total cholesterol and low-density lipoprotein of 4 Chinese wampee seed extract of table
Note: * indicates to indicate and model group difference highly significant with model group significant difference, * *.
Experimental result explanation: compared with model group, total cholesterol and low close can be reduced after extract drug treatment of the present invention
Lipoprotein levels are spent, low dose group and high dose group total cholesterol rate of descent are respectively 16.08% and 40.94%, low dose group
It is respectively 46.81% and 68.27% with high dose group low-density lipoprotein rate of descent.It is fabulous to show that extract of the present invention has
Effect for reducing blood fat, and show certain concentration dependent.
4.4, intestinal flora is tested
Analysis of intestinal microflora result is shown in Fig. 3.
Experimental result explanation: high lipid food dramatically increases the quantity of Firmicutes, and reduces the quantity of Bacteroidetes, this hair
Bright extract effectively reverses this variation, and shows certain concentration dependent.Compared with model group, extract of the present invention
It can increase Bacteroidetes bacterium after drug treatment, and reduce Firmicutes bacterium.
To sum up, extract of the present invention has the function of fabulous hypoglycemic, enhancing insulin sensitivity；Weight-reducing, lipid-loweringing with
And the effect of balance intestinal flora, and show certain concentration dependent.The utilization rate of Calusena lansium is improved, there is wide city
Field application prospect.
Claims (19)
1. Chinese wampee seed and its extract are in preparation prevention and/or treatment diabetes, obesity, the food of hyperlipidemia, health care product
Or the purposes in drug.
2. purposes according to claim 1, it is characterised in that: the Chinese wampee seed is rutaceae Calusena lansium Clausena
The fruit stone of lansium (Lour.) Skeels.
3. purposes according to claim 1, it is characterised in that: the extract of the Chinese wampee seed is water extract or has
Solvent extract.
4. purposes according to claim 3, it is characterised in that: the water extract of the Chinese wampee seed is made as follows
It is standby: to take Chinese wampee seed, crush, add water to extract at 25 ± 5 DEG C 3 times, extract 24~72 hours every time, filter, merging filtrate is dense
Contracting is to get water extract.
5. purposes according to claim 4, it is characterised in that: the w/v of the Chinese wampee seed and water is 1g:(3
~5) ml.
6. purposes according to claim 3, it is characterised in that: the extractive with organic solvent of the Chinese wampee seed is according to as follows
Method preparation:
1) Chinese wampee seed is taken, is crushed, with petroleum ether degreasing, filtering；
2) filter residue obtained by step 1) is taken, ethyl alcohol is added and extracts, is concentrated to get medicinal extract；
3) medicinal extract obtained by step 2) is taken, it is soluble in water, with extracting n-butyl alcohol, water position is collected, concentration is to get organic solvent extraction
Object.
7. purposes according to claim 6, it is characterised in that: in step 1), the bulking value of Chinese wampee seed and petroleum ether
Than for 1g:(3~5) ml.
8. purposes according to claim 6 or 7, it is characterised in that: in step 2), the w/v of filter residue and ethyl alcohol is
1g:(3~5) ml.
9. according to purposes described in claim 5-7 any one, it is characterised in that: in step 2), the volumetric concentration of ethyl alcohol is
65~95%；Preferably, the volumetric concentration of ethyl alcohol is 95%.
10. according to purposes described in claim 6-9 any one, it is characterised in that: in step 3), the weighing body of medicinal extract and water
Product is than being 1g:(5~8) ml.
11. a kind of Chinese wampee seed water extract, it is characterised in that: take Chinese wampee seed, crush, water is added to extract 3 at 25 ± 5 DEG C
It is secondary, it extracts 24~72 hours every time, filtering, merging filtrate is concentrated to get water extract.
12. extract according to claim 11, it is characterised in that: the w/v of the Chinese wampee seed and water is
1g:(3~5) ml.
13. a kind of Chinese wampee seed extractive with organic solvent, it is characterised in that: it is prepared as follows:
1) Chinese wampee seed is taken, is crushed, with petroleum ether degreasing, filtering；
2) filter residue obtained by step 1) is taken, ethyl alcohol is added and extracts, is concentrated to get medicinal extract；
3) medicinal extract obtained by step 2) is taken, is dissolved in distilled water, with extracting n-butyl alcohol, water position is collected, is concentrated to get organic solvent
Extract.
14. extract according to claim 13, it is characterised in that: in step 1), the weight of Chinese wampee seed and petroleum ether
Volume ratio is 1g:(3~5) ml.
15. extract described in 3 or 14 according to claim 1, it is characterised in that: in step 2), the weighing body of filter residue and ethyl alcohol
Product is than being 1g:(3~5) ml.
16. extract described in 3-15 any one according to claim 1, it is characterised in that: in step 2), the volume of ethyl alcohol is dense
Degree is 65-95%；Preferably, the volumetric concentration of ethyl alcohol is 95%.
17. Chinese wampee seed extractive with organic solvent described in 3-16 any one according to claim 1, it is characterised in that: step
3) in, the w/v of medicinal extract and water is 1g:(5~8) ml.
18. extract described in claim 11-17 any one is in food, health care product or the medicine of preparation enhancing insulin sensitivity
Purposes in object.
19. extract described in claim 11-17 any one is in the food, health care product or drug for preparing balance intestinal flora
Purposes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710909565.5A CN109568420A (en) | 2017-09-29 | 2017-09-29 | The purposes of Chinese wampee seed and its extract in the food, health care product or drug of preparation treatment diabetes, obesity and hyperlipidemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710909565.5A CN109568420A (en) | 2017-09-29 | 2017-09-29 | The purposes of Chinese wampee seed and its extract in the food, health care product or drug of preparation treatment diabetes, obesity and hyperlipidemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109568420A true CN109568420A (en) | 2019-04-05 |
Family
ID=65919080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710909565.5A Pending CN109568420A (en) | 2017-09-29 | 2017-09-29 | The purposes of Chinese wampee seed and its extract in the food, health care product or drug of preparation treatment diabetes, obesity and hyperlipidemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109568420A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110327394A (en) * | 2019-08-16 | 2019-10-15 | 海南贵本南药科技有限公司 | The extracting method of blood sugar reducing component in clausenae Lansium or its pericarp |
| CN110404029A (en) * | 2019-08-16 | 2019-11-05 | 海南黎药堂生物科技开发有限公司 | A kind of composition and its preparation method and application with effect of lowering blood sugar |
| CN110804079A (en) * | 2019-11-05 | 2020-02-18 | 广东省农业科学院蚕业与农产品加工研究所 | Furocoumarin with DPPIV enzyme inhibitory activity and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103404679A (en) * | 2013-07-15 | 2013-11-27 | 安徽皖山食品有限公司 | Coated peanuts and preparation method thereof |
| CN103504260A (en) * | 2013-09-23 | 2014-01-15 | 安徽凯利粮油食品有限公司 | Garlic seasoning powder and preparation method thereof |
| CN104026476A (en) * | 2014-05-15 | 2014-09-10 | 安徽禾木食品有限公司 | Lipid-lowering health-care rice with fragrance of celery and processing method thereof |
| CN105106757A (en) * | 2015-09-25 | 2015-12-02 | 山东新希望六和集团有限公司 | Fat cow syndrome treatment medicine and preparation method thereof |
-
2017
- 2017-09-29 CN CN201710909565.5A patent/CN109568420A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103404679A (en) * | 2013-07-15 | 2013-11-27 | 安徽皖山食品有限公司 | Coated peanuts and preparation method thereof |
| CN103504260A (en) * | 2013-09-23 | 2014-01-15 | 安徽凯利粮油食品有限公司 | Garlic seasoning powder and preparation method thereof |
| CN104026476A (en) * | 2014-05-15 | 2014-09-10 | 安徽禾木食品有限公司 | Lipid-lowering health-care rice with fragrance of celery and processing method thereof |
| CN105106757A (en) * | 2015-09-25 | 2015-12-02 | 山东新希望六和集团有限公司 | Fat cow syndrome treatment medicine and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 俞雪梅: "黄皮果核水煎剂的神经保护作用及其作用机制研究", 《浙江中医杂志》 * |
| 南朝君: "《食疗、营养与烹调》", 31 January 2014, 中国医药科技出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110327394A (en) * | 2019-08-16 | 2019-10-15 | 海南贵本南药科技有限公司 | The extracting method of blood sugar reducing component in clausenae Lansium or its pericarp |
| CN110404029A (en) * | 2019-08-16 | 2019-11-05 | 海南黎药堂生物科技开发有限公司 | A kind of composition and its preparation method and application with effect of lowering blood sugar |
| CN110804079A (en) * | 2019-11-05 | 2020-02-18 | 广东省农业科学院蚕业与农产品加工研究所 | Furocoumarin with DPPIV enzyme inhibitory activity and preparation method thereof |
| CN110804079B (en) * | 2019-11-05 | 2021-02-12 | 广东省农业科学院蚕业与农产品加工研究所 | Furocoumarin with DPPIV enzyme inhibitory activity and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103222988B (en) | A kind of American-cockroach-extract and its preparation method and application | |
| CN109568420A (en) | The purposes of Chinese wampee seed and its extract in the food, health care product or drug of preparation treatment diabetes, obesity and hyperlipidemia | |
| Li et al. | The anti-hyperglycemic effect of plants in genus Gynura Cass. | |
| CN103127190A (en) | Preparation method of domestic Brazilian ginseng extract, and application thereof in aspects of medicine and health care | |
| CN101843884B (en) | Method for testing quality of antiviral oral liquid for treating hand-foot-and-mouth disease | |
| CN104922173A (en) | Application of radix acanthopanacis trifoliate extract in inhibiting alpha-glucosidase | |
| CN102224924B (en) | Sea cucumber saponin-containing composition and its application in foods and drugs | |
| CN108310050A (en) | Blue or green money willow extract and its preparation and hypoglycemic application | |
| CN105012826B (en) | A kind of intelligence development leaf extract and preparation method thereof, application | |
| CN106938011A (en) | A kind of Chinese medicine and preparation method with hypoglycemic effect | |
| CN104758309B (en) | The purposes of raspberry polysaccharide for reducing blood sugar | |
| CN109248188A (en) | A kind of preparation method and applications of goldspink root extract | |
| CN101019897B (en) | Antitumor medicine composition and its preparation method | |
| CN102366621B (en) | Plant estrogenic effect of acanthopanax biochemical traditional Chinese medicine compound extract and its application | |
| CN108635352A (en) | Magnoflorine is in the Use and preparation method for preparing prevention insomnia antidepressant agents | |
| CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
| CN100545163C (en) | A kind of active ingredient of Chinese herbs compound and preparation and purposes of preventing and treating senile dementia | |
| CN101129604B (en) | Antihypelipidemic traditional Chinese medicine producing method | |
| CN108143756A (en) | A kind of plant hypoglycemic agent and preparation method thereof | |
| CN100536883C (en) | Use of konjak and its extract in preparation of medicine for treating acute and chronic bronchitis | |
| CN110251543A (en) | Become application of the leaf tree conopsea extraction in preparation antidepression natural drug | |
| JP2002233342A (en) | Echevaria glauca tea | |
| CN1524434A (en) | Extractive product of sunflower | |
| CN105663626A (en) | Rhizoma anemarrhenae effective part as well as preparation method and application thereof | |
| CN106822228A (en) | A kind of subprostrate sophora polysaccharide active component and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |